Indwelling Catheters With Bactiguard Silver Alloy Coating to Prevent Catheter-Associated Urinary Tract Infections in Patients With Spinal Cord Injury

Horizon Scanning Bulletin

Issue #1 — September 2014

Technology Overview

Bactiguard silver alloy coating is considered the key feature of the indwelling Bactiguard Infection Protection (BIP) Urinary Catheters, whose latex- or silicone-base models are used to promote bladder emptying and to maintain low-pressure voiding (Bactiguard SE, Stockholm, Sweden).¹

Their proposed ability to reduce the incidence of catheter-associated urinary tract infections (CAUTI) in patients with or without spinal cord injury is presumed to result specifically from their coating with a silver alloy — including other noble metals (i.e., gold, palladium). The antimicrobial properties are intended to prevent the adhesion of bacteria to the inner surface of a catheter and thus preclude the formation of colonies of bacteria (biofilm) that can result in a CAUTI.²⁻⁴ Silver's long-touted therapeutic potential has been attributed to the antimicrobial action of the silver ion (Ag⁺).⁵⁻⁶ A hydrogel layer facilitates their placement.

The Bactiguard coating, which is applied to the catheter’s inner and outer surface, is also available on a second product line (C.R. Bard, Inc., Covington GA):

- BARDEX I.C. anti-infective Foley catheter with Bactiguard silver alloy coating (latex);
- Lubri-Sil I.C. antimicrobial-coated silicone Foley catheter with Bactiguard silver alloy coating (latex-free); and
- BARDEX I.C. Complete Care infection control Foley catheter System with Bactiguard silver alloy coating and Bard hydrogel coating (latex).⁷⁻⁹

C.R. Bard purchases, then applies, the silver alloy coating to its own Foley catheters.
Patient Group

Spinal cord injury is a high-cost health condition for the patient and the individuals, organisations, and health systems charged with caring for them. Global incidence has been estimated at 23 traumatic spinal cord injury cases per million (as at 2007). This estimate includes land transportation, and water-related accidents and falls (especially in the elderly). Regional rates include: North America (40 per million), Western Europe (16 per million), and Australia (15 per million). It has also been estimated that more than a quarter of a million American adults are living with a traumatic spinal cord injury, with approximately 10,000 new injuries occurring annually.

Urinary tract infections constitute a large burden on the health and well-being of patients with spinal cord injury who experience some form of neurogenic lower urinary tract dysfunction, and especially for those who use indwelling urinary catheters to promote bladder emptying and maintain low-pressure voiding. Urinary tract infections are the most common secondary medical complication of spinal cord injury during both acute care and medical rehabilitation. The various pathogenetic factors of neurogenic bladder dysfunction — such as bladder over-distention, vesicoureteral reflux, high-pressure voiding, large post-void residual volume, stones in the urinary tract, outlet obstruction — can compromise the effectiveness of processes that can prevent urinary tract infection. Additionally, the mechanisms responsible for impaired bladder functioning are influenced by factors such as the time since injury, whether the injury is complete or incomplete, and the level of the injury.

The risk of urinary tract infection in spinal cord-injured patients is enhanced by various factors, not least being the especially long-term use of indwelling urinary catheters. Placement of an indwelling urinary catheter provides an additional stable surface to which bacteria can attach and thereby avoid the natural host defenses of the urethral epithelium. For example, they can also serve as a conduit for the ascent of microbes into the bladder. Other variables that increase the risk include:

- Being older than 40 years;
- Exhibiting poorer functional status;
- Having a complete spinal cord injury, as well as one that is at a higher (especially cervical) level; and
- Frequent exposure to antibiotics, which can increase the risk from antibiotic-resistant strains.

The choice of catheter type depends greatly on the patient’s current degree of dysfunction, morbidity and general functional status, and potential risks of adverse events (e.g. allergic reaction) and mortality.

A current guideline reported an incidence of symptomatic urinary infection in male spinal cord-injured patients who chronically used standard indwelling catheters (not coated or impregnated with antimicrobials or antibiotics) to be 2.72/100 person-days. By contrast, 0.41/100 and 0.36/100 person-days were the rates associated with intermittent (self) catheterisation and condom catheterisation, respectively. At the same time, using both clinical
experience and the available evidence to guide their power calculation, investigators in the ongoing and pragmatic randomised trial of Bactiguard-coated catheters (the ESCALE trial) established a conservative estimate of 24.0% as the proportion of spinal cord-injured patients employing indwelling devices who would experience a symptomatic CAUTI.\(^3\) This contrasts with an observed incidence of 12.6% in an in-patient population in the recently completed CATHETER trial.\(^{30,31}\)

Even so, for various reasons the overall epidemiologic picture regarding CAUTI in spinal cord-injured patients who use these catheters has been considered unreliable. Observations have been obtained from dissimilar kinds of patients (exhibiting various risk factors) and via the use of different case definitions and other methodologies varying in terms of their rigour.\(^{12,20-23,29,32-34}\)

**Potential for Impact**

If, as compared with standard catheters, Bactiguard-coated ones can significantly reduce the incidence of CAUTI, then what might also be lessened are the frequency and the intensity of some of the common, increasingly serious instances of morbidity and related complications over the short-term and beyond. Additional complications may include:

- Discomfort;
- Psycho-emotional distress;
- Localised inflammation;
- Physical pain;
- Bacteremia and sepsis;
- Compromised daily functioning;
- Independence and opportunities to work; and
- Diminished quality of life.

The positive impacts of Bactiguard-coated catheters could in turn decrease the need to intervene to deal with these adverse effects (antibiotic use, and visits to, and potentially lengthy stays in, health facilities).\(^{2,18,34-37}\) Improved bladder management strategies overall have helped make mortality less likely to follow events such as sepsis, renal failure, or a bloodstream infection.\(^{2,16,31,37-39}\)

**Advantage Over Existing Care**

The intended comparative advantage of Bactiguard-coated catheters in preventing CAUTI in spinal cord-injured patients is linked to the antimicrobial properties of its silver alloy.\(^2\) Moreover, the prospect that they could perform effectively and safely for longer periods of time than is typically the case with standard indwelling devices could represent an additional advantage, considering that spinal cord-injured patients often require prolonged catheterisation.\(^3\)
Current Treatment Options

Current standards of care for use with spinal cord-injured patients and other populations include catheters manufactured from various materials. These include latex, silicone, a silicone-latex combination, polyvinyl chloride (or PVC), and polytetrafluoroethylene (or PTFE). These are employed for intermittent self-catheterisation or for use as indwelling devices; and although they can be pre-lubricated or may display other properties (hydrophilic, gel reservoir, sterile non-coated), none specifically include a presumed antimicrobial coating.12-15,20-23

As especially prolonged use of indwelling urinary catheters increases the risk of CAUTI, forms of intermittent self-catheterisation might be preferred.18 Condom catheterisation is another option, as are suprapubic indwelling catheters, which require an initial surgical intervention.12,32 Empirical evidence and expert opinion basically agree that the most effective way to prevent urinary tract infections may be to avoid using catheters; and, if required, to minimise the duration of their use.2,13-15,20-23,32,40-42 However, this approach may apply only to a minority of spinal cord-injured patients.

Clinical Effectiveness

No conclusive inference can be drawn in favour of or against the possibility of a short-term (less than 30 days) or long-term (30 days or more) comparative advantage in the effectiveness of indwelling Bactiguard-coated urinary catheters to prevent CAUTI in spinal cord-injured adult or older pediatric patients (acute or non-acute phase).

One registered, ongoing, open, multi-centre and single-blinded (outcome assessors) randomised trial (NCT01803919, ESCALE trial)43 has aimed to examine prospectively and pragmatically the potentially long-term comparative benefits of Bactiguard-coated devices in preventing CAUTI in adult patients requiring at least seven days of catheterisation (n = 742). Each centre will use its own catheter management protocol, and the outcome assessments will take place at up to 30 days, or upon an earlier, clinician-determined removal, whichever comes first. The trial is estimated to be completed in 2015, with trialists recruiting individuals who will receive either the silicone model of the Bactiguard silver alloy-coated Infection Protection (BIP) Urinary Catheter or a standard indwelling one (most silicone or silicone-latex).3 Interim analyses were not planned.

Also in this adult population, a case report has been published. It describes the use of an indwelling silver alloy-coated hydrogel catheter by a single 40-year-old male, who for 23 years had been using a latex indwelling device — changed monthly by his caregiver — to deal with the effects of sixth cervical level American Spinal Injury Association tetraplegia A.4 During the six-month study, monthly changes permitted the physician to insert...
the silver alloy device, with the patient blinded to its identity. After having experienced monthly occurrences of symptomatic CAUTI that required the use of antibiotics in the six months prior to the intervention, no symptomatic CAUTI events were observed during the study. The patient's level of bacteriuria remained unaffected over this period of time; by study's end, with the bacterial flora having changed, only *Escherichia coli* (*E. coli*) was detected.

While other published clinical trial evidence exists — (with possible concerns as to its reliability because of limited or questionable methodologies such as the nearly universal use of asymptomatic bacteriuria as the primary outcome[^2][^3][^15][^17][^19][^23][^30][^32][^40][^42][^44][^52]) — the studies that have employed Bactiguard-coated catheters typically enrolled representatives from the general in-patient population (acute pathologies, elective surgery), and whose data cannot be meaningfully extrapolated to the spinal cord-injured patient population[^2][^3][^8][^20][^22][^30][^31][^40][^42][^45][^48][^53]. Reasons include the recognition that spinal cord-injured patients typically experience a distinctive clinical picture, which, in addition to difficulty voiding the bladder, can encompass a wide variety of types and intensities of signs, symptoms, challenges, and complications. These include:

- Problems emptying the bowel;
- Paralysis, spasticity, and pain;
- Fatigue, malaise, and lethargy;
- Psycho-emotional distress; and
- Difficulties with self-care.

Additionally, there is the need to intervene regularly to deal with these difficulties.

Yet, one of the biggest differences is that many spinal cord-injured patients need urinary catheterisation that lasts considerably longer, if not for life[^2][^4]. However, a recently updated Cochrane review of the available evidence obtained from in-patient populations suggests that silver alloy-coated urinary catheters may not provide a significant short-term comparative advantage in reducing the incidence of symptomatic CAUTI[^54].

### Safety

Regular testing of serum levels and urine revealed no evidence of silver toxicity in the single case study. The patient did not report having had any difficulty seeing at night, experiencing retching or wanting to vomit daily for three or more days, or having failed to have a bowel movement for one week on his current bowel program[^4]. From controlled studies in populations other than spinal cord-injured patients, silver alloy-coated urinary catheters were well-tolerated (no toxic or allergic responses), and were as well-tolerated as standard indwelling ones or those impregnated with an antibiotic[^30][^31][^40][^42][^48][^53]. The possible adverse effects of silver alloy and antimicrobial resistance over the long-term in spinal cord-injured patients may be revealed by the ongoing ESCALE trial.

### Setting for the Technology Use

Some clinical settings in the United States and the United Kingdom, for example, currently employ Bactiguard-coated catheters[^2]. As their management does not appear to require protocols that differ notably from those that are typically already in place in most contexts, it is probable that Bactiguard-coated catheters can be employed in any clinical practice setting in which other indwelling devices are currently being used with
spinal cord-injured patients. In the ongoing, multi-centre ESCALE trial, each facility could employ its in-house protocol.3,4,3 The beneficial outcomes of Bactiguard-coated catheter use in any subgroup of spinal cord-injured patients depend on numerous facilitative factors (setting, training/experience, reliably practising to evidence-based standards, etc.) in addition to what the device itself can bring about.

**Regulatory Approval**

*Table 1: The Status of Bactiguard-Coated Catheter Approvals in Australia, North America, and the United Kingdom*

<table>
<thead>
<tr>
<th>Regulatory Approval</th>
<th>Bactiguard-Coated Devices</th>
<th>Australia</th>
<th>Canada</th>
<th>United States</th>
<th>United Kingdom</th>
</tr>
</thead>
<tbody>
<tr>
<td>C.R. Bard, Inc.</td>
<td>a. BARDEX I.C. Foley catheter with Bactiguard silver alloy technology (12/01/2009)</td>
<td>No approvals identified</td>
<td>b. BARDEX I.C. pediatric Foley catheter (latex) (12/10/1999)</td>
<td>No approval details could be found</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>c. BARDEX Lubri-Sil I.C. Foley catheter (latex) (02/16/1999)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>d. BARDEX I.C. four-way Foley catheter (latex) (11/03/1998)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*As at July 8, 2014.

**Costs**

On a per-unit basis, Bactiguard-coated urinary catheters are typically more expensive than most other options. This is especially the case for latex devices (AUS$13.00 for a BARDEX male and AUS$13.50 for a BARDEX I.C. female catheter), as compared to their latex counterparts from various companies (AUS$2.50 to $9.00). While per-unit prices do overlap somewhat when it comes to many silicone catheters (AUS$12.00 to $13.50 for a BARDEX Lubri-Sil device versus AUS$5.10 to $13.80), the cost of some devices from other companies (AUS$14.95 to $56.40) can exceed that of the Bactiguard-coated ones.55

Moreover, indirect costs of dealing with a spinal cord injury, especially when observed over the long-term such as the loss of productivity across the lifespan, may exceed direct medical and rehabilitation costs.3,20 As the consequences and complications of CAUTI accrue, which include the need to intervene to address them, so do the financial burdens on those systems, organisations, and individuals responsible for providing care for these patients.37 One estimate is that, without singling out any specific patient populations, CAUTI has cost the United
Kingdom’s National Health Service £25 million per year.6

Thus, to help justify their continuing utilisation, as well as their possible wider diffusion, the cost-effectiveness of Bactiguard-coated catheter use in the spinal cord-injured patient population needs to be determined.3 Yet, what needs to be demonstrated first is a reliable and positive benefit-harms profile that is at least equivalent to what has been attributed to the current standards of care.30,31 And, if it is discovered that Bactiguard-coated catheters are more likely to be kept in place in spinal cord-injured patients — CAUTI- and discomfort-free — for notably longer than might otherwise occur through the use of standard ones, their comparative advantage in delaying both the occurrence of CAUTI and the need to intervene professionally to address adverse effects (e.g., fewer catheter changes, antibiotics, readmissions, and lengthy hospital stays) could translate into an annual reduction in total spending.

This might begin to narrow the gap in cost that was defined initially by the difference in the catheters’ per-unit price tags. However, the ability to detect such an advantage in delaying CAUTI for markedly longer periods of time in spinal cord-injured patients would require a definitive study that lasts long enough to observe one. It is debatable whether the ESCALE trial’s assessment of the primary outcome up to 30 days post-catheterisation is long enough. The difference in patterns of longer-term use once again cautions against extrapolating cost-effectiveness data to spinal cord-injured patients from the studies of other patient populations.30,31,41,42,46,57

Implementation Issues

The similarity of procedures to employ and manage catheterisation in spinal cord-injured patients using indwelling devices that are and are not Bactiguard-coated suggest that the current implementation of locally adopted protocols that aim to assure the reliable implementation of practices should suffice in guiding the reliable use of the former.12-15,20-23,58 Add to this understanding the recognition that staff should already have been trained to implement these protocols and it is unlikely that any notable changes at the level of infrastructure or in the costs to bring them about would be required to allow the reliable use of Bactiguard-coated devices.3,43

Report Limitations

Given the paucity of evidence, the possible comparative advantage of Bactiguard-coated catheters in either their clinical effects or cost-effectiveness in any subpopulation of spinal cord-injured patients (adult or pediatric; male or female; in-patient or outpatient) could not be ascertained.

Report Methodology: Literature Search Strategy

A peer-reviewed literature search was conducted using the following bibliographic databases: PubMed, Embase,
EuroScan, and The Cochrane Library (2014, Issue 6). Grey literature was identified by searching relevant sections of the Grey Matters checklist [http://www.cadth.ca/resources/grey-matters]. No filters were applied to limit the retrieval by study type. The search was limited to English language documents published between January 1, 2009 and July 8, 2014. Regular alerts were established to update the search until August 11, 2014.

References


Disclaimer statement and copyright:
The ISCRR Horizon Scanning Bulletin identifies a single new and emerging health technology, treatment, and/or service that may have the potential to improve the lives of people affected by a transport accident, or work-related illnesses and accidents. The bulletin incorporates descriptions of technologies that are not yet used (or widely diffused) in Australia. The contents are based on information from early experience with the technology; however, further evidence may become available in the future. These summaries are not intended to replace professional medical advice. They are compiled as an information service to help inform decision-makers at the Victorian WorkCover Authority (VWA) and Transport Accident Commission (TAC).

While CADTH and ISCRR have taken care in the preparation of this publication to ensure that its contents are accurate, complete, and up to date as of August 2014, CADTH and ISCRR does not make any guarantee to that effect. CADTH and ISCRR are not responsible for any errors or omissions or injury, loss or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the information in this publication or in any of the source documentation.

CADTH is funded by Health Canada and the governments of Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Northwest Territories, Nova Scotia, Nunavut, Ontario, Prince Edward Island, Saskatchewan, and Yukon. CADTH takes sole responsibility for the final form and content of this report. The views expressed herein do not necessarily represent the views of Health Canada or any provincial or territorial government. ISCRR is a joint initiative of the Victorian WorkCover Authority, the Transport Accident Commission, and Monash University. The opinions, findings, and conclusions expressed in this publication are those of the authors and not necessarily those of ISCRR.

Copyright © CADTH 2014. You are permitted to reproduce this document for non-commercial purposes, provided it is not modified when reproduced and appropriate credit is given to CADTH and ISCRR. You may not otherwise copy, modify, translate, post on a website, store electronically, republish, or redistribute any content from this document in any form or by any means without the prior written permission of CADTH and ISCRR.